Bridgecreek Investment Management LLC increased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.7% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 38,885 shares of the medical equipment provider’s stock after acquiring an additional 640 shares during the period. Bridgecreek Investment Management LLC’s holdings in Zimmer Biomet Holdings were worth $4,553,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of ZBH. JPMorgan Chase & Co. grew its position in shares of Zimmer Biomet Holdings by 92.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,279,951 shares of the medical equipment provider’s stock valued at $421,146,000 after acquiring an additional 1,577,874 shares during the period. Harbour Capital Advisors LLC grew its position in shares of Zimmer Biomet Holdings by 13,131.3% during the 2nd quarter. Harbour Capital Advisors LLC now owns 1,302,618 shares of the medical equipment provider’s stock valued at $10,145,000 after acquiring an additional 1,292,773 shares during the period. Longview Partners Guernsey LTD grew its position in shares of Zimmer Biomet Holdings by 17.7% during the 3rd quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock valued at $878,958,000 after acquiring an additional 1,128,973 shares during the period. Koch Industries Inc. lifted its stake in Zimmer Biomet Holdings by 49,697.3% in the 2nd quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock valued at $1,033,000 after buying an additional 1,038,674 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its stake in Zimmer Biomet Holdings by 230.3% in the 1st quarter. Point72 Asset Management L.P. now owns 1,053,500 shares of the medical equipment provider’s stock valued at $128,643,000 after buying an additional 734,500 shares in the last quarter. Hedge funds and other institutional investors own 85.44% of the company’s stock.

ZBH has been the topic of a number of research reports. Morgan Stanley raised their price target on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an “overweight” rating in a research note on Monday, July 17th. Zacks Investment Research lowered shares of Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. BidaskClub lowered shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Canaccord Genuity lowered shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating and decreased their price target for the company from $141.00 to $135.00 in a research note on Friday, July 28th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $135.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 28th. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. Zimmer Biomet Holdings presently has an average rating of “Hold” and an average target price of $134.00.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) traded down $1.09 during trading on Monday, reaching $110.75. 973,400 shares of the company traded hands, compared to its average volume of 1,366,571. Zimmer Biomet Holdings, Inc. has a 12-month low of $95.63 and a 12-month high of $133.49. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.47 and a quick ratio of 0.78. The firm has a market cap of $22,390.00, a P/E ratio of 13.72, a PEG ratio of 1.72 and a beta of 1.17.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet Holdings had a net margin of 8.36% and a return on equity of 16.29%. The company had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. During the same quarter last year, the business posted $1.79 EPS. The firm’s revenue for the quarter was down .8% on a year-over-year basis. research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.03 earnings per share for the current year.

WARNING: This article was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/11/13/bridgecreek-investment-management-llc-has-4-55-million-stake-in-zimmer-biomet-holdings-inc-zbh.html.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.